{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T04:31:56Z","timestamp":1777782716936,"version":"3.51.4"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Foundation of National Facility for Translational Medicine","award":["TMSK-2020-005"],"award-info":[{"award-number":["TMSK-2020-005"]}]},{"name":"Shanghai Municipal Education Commission-Gaofeng Clinical Medicine","award":["2019081"],"award-info":[{"award-number":["2019081"]}]},{"name":"Shanghai Municipal Education Commission-Gaofeng Clinical Medicine","award":["20181703"],"award-info":[{"award-number":["20181703"]}]},{"DOI":"10.13039\/100007219","name":"Shanghai Natural Science Foundation","doi-asserted-by":"publisher","award":["19ZR1452700"],"award-info":[{"award-number":["19ZR1452700"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972208"],"award-info":[{"award-number":["81972208"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81874229"],"award-info":[{"award-number":["81874229"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key Sci-Tech Special Projects of Infectious Diseases of China","award":["2018ZX10732202-002-003"],"award-info":[{"award-number":["2018ZX10732202-002-003"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Almost all currently approved systemic therapies for hepatocellular carcinoma (HCC) failed to achieve satisfactory therapeutic effect. Exploring tailored treatment strategies for different individuals provides an approach with the potential to maximize clinical benefit. Previously, multiple studies have reported that hepatoma cell lines belonging to different molecular subtypes respond differently to the same treatment. However, these studies only focused on a small number of typical chemotherapy or targeted drugs across limited cell lines due to time and cost constraints. To compensate for the deficiency of previous experimental researches as well as link molecular classification with therapeutic response, we conducted a comprehensive in silico screening, comprising nearly 2000 compounds, to identify compounds with subclass-specific efficacy. Here, we first identified two transcriptome-based HCC subclasses (AS1 and AS2) and then made comparison of drug response between two subclasses. As a result, we not only found that some agents previously considered to have low efficacy in HCC treatment might have promising therapeutic effects for certain subclass, but also identified novel therapeutic compounds that were not routinely used as anti-tumor drugs in clinic. Discovery of agents with subclass-specific efficacy has potential in changing the status quo of population-based therapies in HCC and providing new insights into precision oncology.<\/jats:p>","DOI":"10.1093\/bib\/bbaa295","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T11:24:01Z","timestamp":1601983441000},"source":"Crossref","is-referenced-by-count":27,"title":["Exploring subclass-specific therapeutic agents for hepatocellular carcinoma by informatics-guided drug screen"],"prefix":"10.1093","volume":"22","author":[{"given":"Chen","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Liver Surgery and Shanghai Cancer Institute, State Key Laboratory of Oncogenes and Related Genes, Renji Hospital, Shanghai Jiao Tong University School of Medicine, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Immunology, Zhongshan School of Medicine, Sun Yat-sen University, China. She is focusing on multi-omics analysis of hepatocellular carcinoma"},{"name":"State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Ministry of Health, Division of Gastroenterology and Hepatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowen","family":"Huang","sequence":"additional","affiliation":[{"name":"Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhicheng","family":"Liu","sequence":"additional","affiliation":[{"name":"student at Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Jiang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxin","family":"Qin","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Lv","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4977-2189","authenticated-orcid":false,"given":"Cun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery and Shanghai Cancer Institute, State Key Laboratory of Oncogenes and Related Genes, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,11,9]]},"reference":[{"key":"2021072117031003500_ref1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2021072117031003500_ref2","doi-asserted-by":"crossref","first-page":"a021535","DOI":"10.1101\/cshperspect.a021535","article-title":"Treatment of liver cancer","volume":"5","author":"Liu","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2021072117031003500_ref3","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jhep.2019.09.010","article-title":"Molecular therapies for HCC: looking outside the box","volume":"72","author":"Faivre","year":"2020","journal-title":"J Hepatol"},{"key":"2021072117031003500_ref4","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.24543.1","article-title":"Hepatocellular carcinoma: recent advances and emerging medical therapies","volume":"9","author":"Ko","year":"2020","journal-title":"F1000Res"},{"key":"2021072117031003500_ref5","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/hep.20375","article-title":"Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling","volume":"40","author":"Lee","year":"2004","journal-title":"Hepatology"},{"key":"2021072117031003500_ref6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/hep.21467","article-title":"Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets","volume":"45","author":"Boyault","year":"2007","journal-title":"Hepatology"},{"key":"2021072117031003500_ref7","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1158\/0008-5472.CAN-08-0742","article-title":"Focal gains of VEGFA and molecular classification of hepatocellular carcinoma","volume":"68","author":"Chiang","year":"2008","journal-title":"Cancer Res"},{"key":"2021072117031003500_ref8","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1158\/0008-5472.CAN-09-1089","article-title":"Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma","volume":"69","author":"Hoshida","year":"2009","journal-title":"Cancer Res"},{"key":"2021072117031003500_ref9","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/hep.29254","article-title":"Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection","volume":"66","author":"Desert","year":"2017","journal-title":"Hepatology"},{"key":"2021072117031003500_ref10","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/1878-0261.12639","article-title":"Metabolism-associated molecular classification of hepatocellular carcinoma","volume":"14","author":"Yang","year":"2020","journal-title":"Mol Oncol"},{"key":"2021072117031003500_ref11","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/hep.26223","article-title":"Molecular subtype and response to dasatinib, an Src\/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro","volume":"57","author":"Finn","year":"2013","journal-title":"Hepatology"},{"key":"2021072117031003500_ref12","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1038\/emm.2017.164","article-title":"In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment","volume":"50","author":"Hirschfield","year":"2018","journal-title":"Exp Mol Med"},{"key":"2021072117031003500_ref13","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1053\/j.gastro.2019.05.001","article-title":"Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response","volume":"157","author":"Caruso","year":"2019","journal-title":"Gastroenterology"},{"key":"2021072117031003500_ref14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ccell.2019.07.001","article-title":"A pharmacogenomic landscape in human liver cancers","volume":"36","author":"Qiu","year":"2019","journal-title":"Cancer Cell"},{"key":"2021072117031003500_ref15","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","article-title":"A landscape of pharmacogenomic interactions in cancer","volume":"166","author":"Iorio","year":"2016","journal-title":"Cell"},{"key":"2021072117031003500_ref16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nchembio.1986","article-title":"Correlating chemical sensitivity and basal gene expression reveals mechanism of action","volume":"12","author":"Rees","year":"2016","journal-title":"Nat Chem Biol"},{"key":"2021072117031003500_ref17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","article-title":"Discovering the anticancer potential of non-oncology drugs by systematic viability profiling","volume":"1","author":"Corsello","year":"2020","journal-title":"Nature Cancer"},{"key":"2021072117031003500_ref18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/73432","article-title":"Systematic variation in gene expression patterns in human cancer cell lines","volume":"24","author":"Ross","year":"2000","journal-title":"Nat Genet"},{"key":"2021072117031003500_ref19","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1186\/gb-2014-15-3-r47","article-title":"Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines","volume":"15","author":"Geeleher","year":"2014","journal-title":"Genome Biol"},{"key":"2021072117031003500_ref20","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1101\/gr.221077.117","article-title":"Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies","volume":"27","author":"Geeleher","year":"2017","journal-title":"Genome Res"},{"key":"2021072117031003500_ref21","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","article-title":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma","volume":"169","author":"The Cancer Genome Atlas Research Network, David A. Wheeler, Lewis R. Roberts.","year":"2017","journal-title":"Cell"},{"key":"2021072117031003500_ref22","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ng.3547","article-title":"Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer","volume":"48","author":"Fujimoto","year":"2016","journal-title":"Nat Genet"},{"key":"2021072117031003500_ref23","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.cell.2019.10.038","article-title":"Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma","volume":"179","author":"Gao","year":"2019","journal-title":"Cell"},{"key":"2021072117031003500_ref24","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1053\/j.gastro.2011.12.039","article-title":"Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival","volume":"142","author":"Roessler","year":"2012","journal-title":"Gastroenterology"},{"key":"2021072117031003500_ref25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/1878-0261.12153","article-title":"Tumor-adjacent tissue co-expression profile analysis reveals pro-oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma","volume":"12","author":"Grinchuk","year":"2018","journal-title":"Mol Oncol"},{"key":"2021072117031003500_ref26","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"Management of hepatocellular carcinoma","volume":"69","author":"EASL Clinical Practice Guidelines","year":"2018","journal-title":"J Hepatol"},{"key":"2021072117031003500_ref27","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/annonc\/mdy510","article-title":"Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Vogel","year":"2019","journal-title":"Ann Oncol"},{"key":"2021072117031003500_ref28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/hep.30811","article-title":"Clinical impact of genomic diversity from early to advanced hepatocellular carcinoma","volume":"71","author":"Nault","year":"2020","journal-title":"Hepatology"},{"key":"2021072117031003500_ref29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/gm433","article-title":"Computational purification of individual tumor gene expression profiles leads to significant improvements in prognostic prediction","volume":"5","author":"Quon","year":"2013","journal-title":"Genome Med"},{"key":"2021072117031003500_ref30","first-page":"820","article-title":"Computational models for predicting drug responses in cancer research","volume":"18","author":"Azuaje","year":"2017","journal-title":"Brief Bioinform"},{"key":"2021072117031003500_ref31","first-page":"27","article-title":"The stream algorithm: computationally efficient ridge-regression via Bayesian model averaging, and applications to pharmacogenomic prediction of cancer cell line sensitivity","author":"Neto","year":"2014","journal-title":"Pac Symp Biocomput"},{"key":"2021072117031003500_ref32","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","article-title":"Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies","volume":"25","author":"Harding","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2021072117031003500_ref33","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-0439-x","article-title":"ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma","author":"Feng","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"2021072117031003500_ref34","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000504548","article-title":"Gene signature for sorafenib susceptibility in hepatocellular carcinoma: different approach with a predictive biomarker","volume":"9","author":"Kim","year":"2020","journal-title":"Liver Cancer"},{"key":"2021072117031003500_ref35","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/liv.12889","article-title":"Clinicopathological indices to predict hepatocellular carcinoma molecular classification","volume":"36","author":"Tan","year":"2016","journal-title":"Liver Int"},{"key":"2021072117031003500_ref36","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/annonc\/mdf303","article-title":"Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial","volume":"13","author":"Yang","year":"2002","journal-title":"Ann Oncol"},{"key":"2021072117031003500_ref37","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nm0612-842b","article-title":"Cancer drug's survivin suppression called into question","volume":"18","author":"Holmes","year":"2012","journal-title":"Nat Med"},{"key":"2021072117031003500_ref38","doi-asserted-by":"crossref","first-page":"5990","DOI":"10.18632\/oncotarget.3337","article-title":"The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma","volume":"6","author":"Xia","year":"2015","journal-title":"Oncotarget"},{"key":"2021072117031003500_ref39","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.3892\/ol.2015.3451","article-title":"Silencing of survivin by YM155 induces apoptosis and growth arrest in hepatocellular carcinoma cells","volume":"10","author":"Zhang","year":"2015","journal-title":"Oncol Lett"},{"key":"2021072117031003500_ref40","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/liv.14048","article-title":"Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma","volume":"39","author":"Schulte","year":"2019","journal-title":"Liver Int"},{"key":"2021072117031003500_ref41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1042\/bse0470053","article-title":"Mitochondrial proton and electron leaks","volume":"47","author":"Jastroch","year":"2010","journal-title":"Essays Biochem"},{"key":"2021072117031003500_ref42","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ccr.2013.05.003","article-title":"Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells","volume":"23","author":"Roesch","year":"2013","journal-title":"Cancer Cell"},{"key":"2021072117031003500_ref43","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"2021072117031003500_ref44","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"2021072117031003500_ref45","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor Signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"2021072117031003500_ref46","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-019-1607-3","article-title":"Inducing and exploiting vulnerabilities for the treatment of liver cancer","volume":"574","author":"Wang","year":"2019","journal-title":"Nature"},{"key":"2021072117031003500_ref47","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"}],"container-title":["Briefings in Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/bib\/article-pdf\/22\/4\/bbaa295\/39143673\/bbaa295.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bib\/article-pdf\/22\/4\/bbaa295\/39143673\/bbaa295.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T17:24:58Z","timestamp":1626888298000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bib\/article\/doi\/10.1093\/bib\/bbaa295\/5960426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7,20]]}},"URL":"https:\/\/doi.org\/10.1093\/bib\/bbaa295","relation":{},"ISSN":["1467-5463","1477-4054"],"issn-type":[{"value":"1467-5463","type":"print"},{"value":"1477-4054","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7]]},"published":{"date-parts":[[2020,11,9]]},"article-number":"bbaa295"}}